drugset / Trial / NCT04071379

Comparison of Immunogenicity and Safety of DTP-HB-Hib (Bio Farma) With Pentabio® Vaccine Primed With Recombinant Hepatitis B

NCT04071379 ↗

Phase 3 Completed 220 enrolled PT Bio Farma
RandomizedParallel-groupDouble-blindPrevention

Summary

Comparison of Immunogenicity and Safety of DTP-HB-Hib (Bio Farma) with Pentabio® vaccine Primed with Recombinant Hepatitis B

Timeline

Start
2020-10-13
Primary completion
2021-04-06
Completion
2021-12-16

Drugs

EvaluationDrugModalityDoseRoute
Subject DTP-HB-Hib Unknown 0.5 ml —
Comparator Pentabio Vaccine 0.5 ml —
Subject Recombinant Hepatitis B Unknown 0.5 ml —

Indications

No indication recorded.